TP53 and neoplasm: The primary tumor had a low-level pathogenic TP53 mutation with AAF of 1.2%, which increased to 32.9% in the recurrence, suggesting the outgrowth of a nonLOH TP53-mutant subclone (Supplementary Data 3).